Lineage Cell Therapeutics Inc (LCTX) Stock Price, Quote & News

Company Profile

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for th...

Industry: Biotechnology

Sector: Healthcare

Phone: 442 287 8990

Website: www.lineagecell.com

Address:

2173 Salk Avenue, Suite 200, Carlsbad, United States

Goodhealth Aug. 4 at 11:20 AM

$LCTX https://www.ddw-online.com/are-cell-therapies-the-answer-to-age-related-eye-diseases-42892-202607/ ...... https://www.youtube.com/watch?v=wXamuo9kZjA

1 · Reply

Logic102 Aug. 4 at 3:14 AM

$LCTX First gap to fill is 1.345 then to 1 71 then to 1.95. Of course, the right news could take us immediately to 2.50+

1 · Reply

qwertylicious2003 Aug. 4 at 1:49 AM

$LCTX another good hire. Read up on some of the research she’s been involved with in RPE transplantation. Building the moat and army, brick by brick.

1 · Reply

tiddyy Aug. 3 at 5:51 PM

$LCTX Hello friends, I have bought some shares, long hold for me

2 · Reply

dannyschell Aug. 3 at 5:51 PM

$LCTX not much anticipation of upcoming quarterly report.

0 · Reply

Shaftertoz Aug. 3 at 1:12 PM

$LCTX Does anyone have Level 2 access for $LCTX? What's the lowest bid / support level showing? Thanks

2 · Reply

Ablidy Aug. 3 at 11:58 AM

$LCTX

0 · Reply

Logic102 Aug. 3 at 11:42 AM

$LCTX End of day bottom is in at 1.03 and the first significant gap to fill is 1.34, eventually back into the 1.70s. Easy to spot Asymmetric Risk Reward situations are Fun for the entire Family!

2 · Reply

qwertylicious2003 Aug. 3 at 11:01 AM

$LCTX EarlySight identified 60% more drusen then OCT. Crazy to see what this tech (included in the GAlette trial) can tell us. https://www.mdpi.com/2073-4409/14/9/633

0 · Reply

Logic102 Aug. 2 at 1:14 PM

$LCTX @imatisse Excellent parallel with $TSLA imo. It's all about who has the technology platform during the Paradigm Shift and who has laid the groundwork to control the production. Better mousetrap parallels with $NVDA as well.

0 · Reply

Lineage Cell Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026

LCTX

Jul 13, 2026, 4:30 PM EDT - 21 days ago

Lineage Cell Therapeutics Transcript: Study update

Jul 13, 2026, 4:30 PM EDT - 21 days ago

Lineage Cell Therapeutics Press release: Study update

2026-07-13T12:05:45.000Z - 22 days ago

Lineage Cell Therapeutics provides update on COR1 program

LCTX

Jul 13, 2026, 8:00 AM EDT - 22 days ago

Lineage Provides Update on COR1 Cell Therapy Program for Corneal Endothelial Disease

LCTX

Jul 6, 2026, 8:00 AM EDT - 4 weeks ago

Lineage Cell Therapeutics to Present at B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit

LCTX

2026-05-12T22:11:23.000Z - 2 months ago

Lineage Cell Therapeutics reports Q1 EPS (3c), consensus (2c)

LCTX

May 12, 2026, 4:30 PM EDT - 2 months ago

Lineage Cell Therapeutics Earnings Call Transcript: Q1 2026

May 12, 2026, 4:30 PM EDT - 2 months ago

Lineage Cell Therapeutics Earnings release: Q1 2026

May 12, 2026, 4:30 PM EDT - 2 months ago

Lineage Cell Therapeutics Quarterly report: Q1 2026

May 12, 2026, 4:01 PM EDT - 2 months ago

Lineage Cell Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

LCTX

May 12, 2026, 7:00 AM EDT - 3 months ago

Lineage Cell Therapeutics Slides: Corporate presentation

May 5, 2026, 8:00 AM EDT - 3 months ago

Lineage Cell Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 12, 2026

LCTX

May 4, 2026, 8:00 AM EDT - 3 months ago

OpRegen® 3 Year Results in Patients With GA Presented at Foundation Fighting Blindness Retinal Innovation Summit 2026

LCTX

Apr 29, 2026, 8:00 AM EDT - 3 months ago

Lineage Cell Therapeutics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 3 months ago

Lineage Cell Therapeutics Proxy statement: Proxy filing

2026-04-28T11:14:03.000Z - 3 months ago

Lineage Cell Therapeutics initiated with a Buy at Canaccord

LCTX

2026-04-13T12:26:16.000Z - 4 months ago

Lineage Cell Therapeutics announces formation of Scientific Advisory Board

LCTX

Apr 13, 2026, 8:00 AM EDT - 4 months ago

Lineage Announces Formation of Scientific Advisory Board

LCTX

2026-04-08T20:56:34.000Z - 4 months ago

Lineage Cell Therapeutics management to meet with Craig-Hallum

LCTX

2026-03-25T12:16:37.000Z - 4 months ago

Lineage Cell Therapeutics price target raised to $4 from $3 at B. Riley

LCTX

Mar 25, 2026, 7:00 AM EDT - 4 months ago

Lineage Cell Therapeutics Slides: Corporate presentation

Mar 24, 2026, 8:00 AM EDT - 4 months ago

Lineage Launches New Cell Therapy Program in Corneal Endothelial Disease

LCTX

Mar 11, 2026, 8:00 AM EDT - 5 months ago

Lineage Cell Therapeutics Registration statement: Registration Filing

Mar 5, 2026, 4:30 PM EST - 5 months ago

Lineage Cell Therapeutics Earnings Call Transcript: Q4 2025

Mar 5, 2026, 4:30 PM EST - 5 months ago

Lineage Cell Therapeutics Annual report: Q4 2025

Mar 5, 2026, 4:30 PM EST - 5 months ago

Lineage Cell Therapeutics Earnings release: Q4 2025

2026-03-05T21:11:09.000Z - 5 months ago

Lineage Cell Therapeutics reports Q4 EPS 0c vs (2c) last year

LCTX

Mar 5, 2026, 4:01 PM EST - 5 months ago

Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

LCTX

Feb 26, 2026, 8:00 AM EST - 5 months ago

Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026

LCTX

2026-02-20T14:15:55.000Z - 5 months ago

Lineage Cell Therapeutics management to meet with B, Riley

LCTX

2026-01-06T13:15:39.000Z - 7 months ago

Lineage Cell Therapeutics receives iPSC line from Factor Bioscience

LCTX

Jan 6, 2026, 8:00 AM EST - 7 months ago

Lineage Takes Delivery of Gene-edited Hypoimmune Cell Line Under Partnership With Factor Bioscience

LCTX

Jan 5, 2026, 8:00 AM EST - 7 months ago

Lineage Cell Therapeutics Issues Letter to Stockholders

LCTX

Nov 6, 2025, 4:30 PM EST - 9 months ago

Lineage Cell Therapeutics Earnings Call Transcript: Q3 2025

Nov 6, 2025, 4:30 PM EST - 9 months ago

Lineage Cell Therapeutics Quarterly report: Q3 2025

Nov 6, 2025, 4:30 PM EST - 9 months ago

Lineage Cell Therapeutics Earnings release: Q3 2025

2025-11-06T21:12:07.000Z - 9 months ago

Lineage Cell Therapeutics reports Q3 EPS (13c), consensus (3c)

LCTX

Nov 6, 2025, 4:01 PM EST - 9 months ago

Lineage Cell Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

LCTX

Oct 30, 2025, 8:00 AM EDT - 9 months ago

Lineage Cell Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025

LCTX

Sep 8, 2025, 11:30 AM EDT - 11 months ago

Lineage Cell Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

2025-09-08T12:10:26.000Z - 11 months ago

Lineage Cell Therapeutics initiates new islet cell transplant program

LCTX

Sep 8, 2025, 8:00 AM EDT - 11 months ago

Lineage Cell Therapeutics Initiates Cell Transplant Program In Type 1 Diabetes

LCTX

Sep 2, 2025, 8:00 AM EDT - 1 year ago

Lineage Cell Therapeutics to Present at September 2025 Investor Conferences

LCTX

2025-08-26T12:05:19.000Z - 1 year ago

Lineage Cell Therapeutics enters research pact with William Demant Invest

LCTX

Aug 26, 2025, 8:00 AM EDT - 1 year ago

Lineage Announces Research Collaboration With William Demant Invest to Develop ReSonance™ (ANP1) for Hearing Loss

LCTX

Aug 12, 2025, 4:30 PM EDT - 1 year ago

Lineage Cell Therapeutics Earnings Call Transcript: Q2 2025

Aug 12, 2025, 4:30 PM EDT - 1 year ago

Lineage Cell Therapeutics Quarterly report: Q2 2025

Aug 12, 2025, 4:30 PM EDT - 1 year ago

Lineage Cell Therapeutics Earnings release: Q2 2025

2025-08-12T20:06:19.000Z - 1 year ago

Lineage Cell Therapeutics reports Q2 EPS (13c), consensus (3c)

LCTX

Aug 12, 2025, 4:01 PM EDT - 1 year ago

Lineage Cell Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

LCTX

Aug 5, 2025, 8:00 AM EDT - 1 year ago

Lineage Cell Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025

LCTX

2025-08-04T12:12:07.000Z - 1 year ago

Lineage Cell Therapeutics doses first patient in DOSED study

LCTX

Aug 4, 2025, 8:00 AM EDT - 1 year ago

Lineage Announces Dosing of First Patient in New Clinical Study of OPC1 for Subacute and Chronic Spinal Cord Injury

LCTX

Jun 23, 2025, 7:00 AM EDT - 1 year ago

OpRegen® (RG6501) 36-Month Visual Acuity Results Featured at Clinical Trials at the Summit 2025

LCTX

Jun 11, 2025, 8:00 AM EDT - 1 year ago

Lineage Cell Therapeutics Proxy statement: Proxy Filing

Jun 5, 2025, 8:00 AM EDT - 1 year ago

Lineage Cell Therapeutics Announces Updates to the 3rd Annual Spinal Cord Injury Investor Symposium

LCTX

May 20, 2025, 2:30 PM EDT - 1 year ago

Lineage Cell Therapeutics Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 14, 2025, 8:00 AM EDT - 1 year ago

Lineage to Present at 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC

LCTX

May 13, 2025, 4:30 PM EDT - 1 year ago

Lineage Cell Therapeutics Earnings Call Transcript: Q1 2025

May 13, 2025, 4:30 PM EDT - 1 year ago

Lineage Cell Therapeutics Quarterly report: Q1 2025

May 13, 2025, 4:30 PM EDT - 1 year ago

Lineage Cell Therapeutics Earnings release: Q1 2025

May 13, 2025, 4:01 PM EDT - 1 year ago

Lineage Cell Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

LCTX

May 12, 2025, 8:00 AM EDT - 1 year ago

RG6501 (OpRegen®) Phase 1/2a Clinical Study 36 Month Results to Be Featured at Clinical Trials at the Summit 2025

LCTX

May 1, 2025, 8:00 AM EDT - 1 year ago

Lineage Cell Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025

LCTX

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Lineage Cell Therapeutics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Lineage Cell Therapeutics Proxy statement: Proxy Filing

Apr 22, 2025, 8:00 AM EDT - 1 year ago

Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 3rd Annual Spinal Cord Injury Investor Symposium

LCTX

Apr 21, 2025, 8:00 AM EDT - 1 year ago

Lineage to Present at 2025 Eyecelerator Meeting Sponsored by the American Academy of Ophthalmology (AAO)

LCTX

Mar 10, 2025, 4:30 PM EDT - 1 year ago

Lineage Cell Therapeutics Earnings Call Transcript: Q4 2024

Mar 10, 2025, 4:30 PM EDT - 1 year ago

Lineage Cell Therapeutics Annual report: Q4 2024

Mar 10, 2025, 4:30 PM EDT - 1 year ago

Lineage Cell Therapeutics Earnings release: Q4 2024

Mar 10, 2025, 4:05 PM EDT - 1 year ago

Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

LCTX

Mar 5, 2025, 8:00 AM EST - 1 year ago

Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on March 10, 2025

LCTX

Feb 11, 2025, 12:40 PM EST - 1 year ago

Lineage Cell Therapeutics Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Feb 11, 2025, 12:40 PM EST - 1 year ago

Lineage Cell Therapeutics Slides: FY 2025

Feb 11, 2025, 8:00 AM EST - 1 year ago

Lineage Initiates Clinical Study of OPC1 for Spinal Cord Injury

LCTX

Feb 4, 2025, 8:00 AM EST - 1 year ago

Lineage Cell Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Lifesciences Conference

LCTX

Jan 27, 2025, 4:05 PM EST - 1 year ago

Lineage Cell Therapeutics Announces Closing of Second Tranche of Previously Announced Registered Direct Offering

LCTX

Dec 9, 2024, 7:00 AM EST - 1 year ago

Lineage Cell Therapeutics Proxy statement: Proxy Filing

Nov 29, 2024, 7:00 AM EST - 1 year ago

Lineage Cell Therapeutics Proxy statement: Proxy Filing

Nov 21, 2024, 5:00 PM EST - 1 year ago

Lineage Cell Therapeutics Announces First Closing of up to $66 Million Registered Direct Offering

LCTX

Nov 20, 2024, 8:00 AM EST - 1 year ago

Lineage Cell Therapeutics Announces Pricing of up to $66 Million Registered Direct Offering

LCTX

Nov 14, 2024, 4:30 PM EST - 1 year ago

Lineage Cell Therapeutics Earnings Call Transcript: Q3 2024

Nov 14, 2024, 4:30 PM EST - 1 year ago

Lineage Cell Therapeutics Quarterly report: Q3 2024

Nov 14, 2024, 4:30 PM EST - 1 year ago

Lineage Cell Therapeutics Earnings release: Q3 2024

Nov 14, 2024, 4:01 PM EST - 1 year ago

Lineage Cell Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

LCTX

Nov 7, 2024, 8:00 AM EST - 1 year ago

Lineage Cell Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024

LCTX

Oct 14, 2024, 8:00 AM EDT - 1 year ago

Lineage Cell Therapeutics to Present at the Maxim Group 2024 Virtual Healthcare Summit

LCTX

Sep 25, 2024, 8:00 AM EDT - 2 years ago

OpRegen® (RG6501) Phase 1/2a Results to Be Featured at International Society for Stem Cell Research (ISSCR) 2024 Copenhagen International Symposium

LCTX

Sep 18, 2024, 8:00 AM EDT - 2 years ago

Lineage Presents Preclinical Data on Its Auditory Neuronal Cell Transplant Program, ReSonance™, at the 59th Annual Inner Ear Biology Workshop

LCTX

Aug 15, 2024, 7:00 AM EDT - 2 years ago

Lineage Cell Therapeutics Transcript: H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Aug 13, 2024, 8:00 AM EDT - 2 years ago

Lineage Cell Therapeutics to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

LCTX

Aug 8, 2024, 4:30 PM EDT - 2 years ago

Lineage Cell Therapeutics Earnings Call Transcript: Q2 2024

Aug 8, 2024, 4:30 PM EDT - 2 years ago

Lineage Cell Therapeutics Quarterly report: Q2 2024

Aug 8, 2024, 4:30 PM EDT - 2 years ago

Lineage Cell Therapeutics Earnings release: Q2 2024

Aug 8, 2024, 4:05 PM EDT - 2 years ago

Lineage Cell Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

LCTX

Aug 1, 2024, 8:00 AM EDT - 2 years ago

Lineage Cell Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024

LCTX

Jul 2, 2024, 8:00 AM EDT - 2 years ago

Lineage Cell Therapeutics Added to Membership of 2024 Russell 3000® Index

LCTX

May 30, 2024, 8:00 AM EDT - 2 years ago

Lineage to Present at 2024 BIO International Convention

LCTX

May 21, 2024, 8:00 AM EDT - 2 years ago

Lineage Announces Updates to 2nd Annual Spinal Cord Injury Investor Symposium

LCTX

May 9, 2024, 4:30 PM EDT - 2 years ago

Lineage Cell Therapeutics Earnings Call Transcript: Q1 2024

May 9, 2024, 4:30 PM EDT - 2 years ago

Lineage Cell Therapeutics Quarterly report: Q1 2024

May 9, 2024, 4:30 PM EDT - 2 years ago

Lineage Cell Therapeutics Earnings release: Q1 2024

May 9, 2024, 4:01 PM EDT - 2 years ago

Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

LCTX

May 6, 2024, 8:00 AM EDT - 2 years ago

OpRegen® (RG6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit

LCTX

May 2, 2024, 8:00 AM EDT - 2 years ago

Lineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024

LCTX

Apr 30, 2024, 8:00 AM EDT - 2 years ago

Lineage Receives Grant From California Institute for Regenerative Medicine (CIRM)

LCTX

Goodhealth Aug. 4 at 11:20 AM

$LCTX https://www.ddw-online.com/are-cell-therapies-the-answer-to-age-related-eye-diseases-42892-202607/ ...... https://www.youtube.com/watch?v=wXamuo9kZjA

1 · Reply

Logic102 Aug. 4 at 3:14 AM

$LCTX First gap to fill is 1.345 then to 1 71 then to 1.95. Of course, the right news could take us immediately to 2.50+

1 · Reply

qwertylicious2003 Aug. 4 at 1:49 AM

$LCTX another good hire. Read up on some of the research she’s been involved with in RPE transplantation. Building the moat and army, brick by brick.

1 · Reply

tiddyy Aug. 3 at 5:51 PM

$LCTX Hello friends, I have bought some shares, long hold for me

2 · Reply

dannyschell Aug. 3 at 5:51 PM

$LCTX not much anticipation of upcoming quarterly report.

0 · Reply

Shaftertoz Aug. 3 at 1:12 PM

$LCTX Does anyone have Level 2 access for $LCTX? What's the lowest bid / support level showing? Thanks

2 · Reply

Ablidy Aug. 3 at 11:58 AM

$LCTX

0 · Reply

Logic102 Aug. 3 at 11:42 AM

$LCTX End of day bottom is in at 1.03 and the first significant gap to fill is 1.34, eventually back into the 1.70s. Easy to spot Asymmetric Risk Reward situations are Fun for the entire Family!

2 · Reply

qwertylicious2003 Aug. 3 at 11:01 AM

$LCTX EarlySight identified 60% more drusen then OCT. Crazy to see what this tech (included in the GAlette trial) can tell us. https://www.mdpi.com/2073-4409/14/9/633

0 · Reply

Logic102 Aug. 2 at 1:14 PM

0 · Reply

Gromit00 Aug. 1 at 11:32 PM

$LCTX August 4th will be one year since they announced the dosing of the 1st chronic patient with OPC1. I wonder if we will get any kind of update on Thursday.

2 · Reply

gerson999 Aug. 1 at 2:41 PM

$LCTX nice setup. The seller is gone. can anyone believe that Roche will not move GAlette (OpRegen) to phase 3? The price went to $2.09 on November 3 2025 in anticipation of this. What is remarkable is that the delay that has caused the price to plummet is because the findings have proven to expand the value of the therapy significantly. Thus Roche has expanded and extended the trial to capture those benefits. Now its your turn to take advantage of this wonderful opportunity.

4 · Reply

imatisse Aug. 1 at 12:20 PM

$TSLA wasn’t valued as just another car company. #Wallstreet saw the manufacturing platform as the moat. What if ? $LCTX ❤️ has the same #perception gap? Maybe 👁️ OpRegen is the Roadster. The real story is #AlloSCOPE: Scalable, Off-the-shelf Cell-Manufacturing #Platform #dryamd ✅ Platforms change everything. **** Hundreds of patients who currently face inevitable vision loss despite existing therapies!

0 · Reply

primordialATOM Jul. 31 at 1:50 PM

$LCTX I feel a need for more cow bell .... Bang that bell .... Harder and longer .... Until the cows come dancing home ....

1 · Reply

Logic102 Jul. 31 at 10:52 AM

$LCTX $ORCL Shorting these names is a Fool's errand. Your trusted Algos can flip on you hard in a hurry bears. Dangerous game.

0 · Reply

Logic102 Jul. 31 at 10:48 AM

$LCTX Just 1270 shares PreMarket, but up 8.11% did get my attention. Maybe nothing but that's not just 5 shares.

1 · Reply

smzal Jul. 31 at 9:01 AM

$LCTX Crazy thought… 🤔 What if OpRegen isn’t just validating a therapy, but an entire manufacturing platform? If so, does VAC2 become a forgotten asset… or a future deal? #CellTherapy #Biotech

1 · Reply

qwertylicious2003 Jul. 31 at 1:09 AM

$LCTX interesting article. I’ve gone through two rounds of this treatment and have remained relatively stable. What is really eye opening is the value of one extra year of “healthy life”. Useful for estimating the value of OpRegen which restores vision and “healthy life”. https://www.reviewofoptometry.com/article/study-shows-dry-iamd-light-therapy-is-costeffective?fbclid=IwdGRleATY1HNwZG9mAWZkaWQWULmDiwuWM8TdKm9kuu_Xvnl-wqrk1WV4dG4DYWVtAjExAHNydGMGYXBwX2lkCjY2Mjg1NjgzNzkAAR5jEnkkFKv5BpgKQZrzz1_7x5RVXDGlfpiluXK_2rBX5cffHIM8VR7pwycV3Q_aem_X6PAJVvBupgxF5muX0nrtA

2 · Reply

Logic102 Jul. 30 at 10:41 PM

$LCTX Triple ones are half way to triple twos 2.22 and one-tenth to double elevens 11.11 (these numbers are quite possible with the correct news).

1 · Reply

Ablidy Jul. 30 at 4:03 PM

$LCTX paradigm shift on twitter https://x.com/ablidy/status/2082852481739210969

0 · Reply

Logic102 Jul. 30 at 4:00 PM

$LCTX Speaking of Supply and Demand, when there's no big Seller as there has been recently, the supply of shares is quite low, so any demand really drives up the share price quickly as illustrated today. There's a lot of retail on this thread with a pretty large Supply of shares that are not selling. That bodes well as demand could increase dramatically with the correct news.

2 · Reply

gerson999 Jul. 30 at 3:57 PM

$LCTX short interest off the charts? almost 30 million shares?

0 · Reply

Market Cap	269.24M
Revenue (ttm)	14.56M
Net Income (ttm)	-63.53M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-436.33%
Debt to Equity Ratio	0.00

Volume	680,700
Avg Vol	1,473,836
Day's Range	N/A - N/A
Shares Out	249.30M
Stochastic %K	81%
Beta	1.51
Analysts	Strong Sell
Price Target	$5.14